leadf
logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics says AxisBiotix subsidiary has commenced enrolment for its food supplement consumer study

A proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis

Researchers
Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby raised 'plaques' form on the skin, which can be flaky, scaly and itchy

SkinBioTherapeutics PLC (LON:SBTX), a life science company focused on skin health, announced that AxisBiotix Limited, a wholly-owned subsidiary of the company, has commenced enrolment for its food supplement consumer study.

Further to research exploring the relationship between the gut and the skin and the scientific evidence pointing to a link between gut dysfunction, stress-induced alterations to the gut microbiome and skin inflammation, the company noted that it has been working with Winclove Probiotics B.V. for the development of a blend of bacterial strains as a food supplement.

A proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis. Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby raised 'plaques' form on the skin, which can be flaky, scaly and itchy.

READ: SkinBioTherapeutics preparing to kick off psoriasis study as it eyes a busy year

There is currently no cure for psoriasis; therapies tend to be steroid-based, which cannot be used long term and have side effects. The condition is common, with approximately 2% of the global population believed to suffer from psoriasis.

With Winclove having completed formulation and manufacture of the supplement, and unable to initiate its clinic-based human study due to the coronavirus (COVID-19) restrictions, SkinBioTherapeutics has established a protocol for a 'self-managed' food supplement study.

The study, which will accept approximately 200 applicants, is now open for enrolment through the website www.axisbiotix.com. The participants will be asked to take a powdered food supplement dissolved in a glass of water on a daily basis and the study will run for a total of 56 days (2 x 28-day blocks).

Thereafter the data will be collated and analysed to assess the impact the supplement has had on the health of the skin. The study is monitored through a mobile phone application with frequent questions for participants and the submission of photographs of affected areas taken using their smart devices. As such the study is not impacted by current COVID-19 restrictions.

The supplements have been manufactured by Winclove and are currently being packaged ahead of shipment to the company in early February. The supplements will then be dispatched to the study participants with an expected start date before the end of February 2021.

The study will conclude before the end of April 2021 and the company expects to be able to report on the study findings shortly thereafter. Subject to a positive outcome, the company will then target a commercial launch of the product during the course of 2021 and in parallel initiate a clinic-based study looking at specific markers.

In a statement, Stuart Ashman, CEO of SkinBioTherapeutics, commented: "2020 was a year of transition for SkinBioTherapeutics with a focus on flexibility. We managed a smooth evolution from research into development, and proactively managed our way around the ever-changing obstacles that the global pandemic presented and continues to present.

"The preparatory work carried out last year has ensured that we remain on track with all our strategic and commercial goals as we move into 2021, where we expect to see significant progress across several of our strategic channels. The launch of the AxisBiotix website and the recruitment of candidates for our AxisBiotix-PS study, as well as the ongoing progress made by Sederma with our skincare programme, heralds the start of our commercialisation drive."

Quick facts: SkinBioTherapeutics PLC

Price: 38.075 GBX

AIM:SBTX
Market: AIM
Market Cap: £59.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Skinbiotherapeutics get set for live data trial to target skin conditions...

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their wholly-owned subsidiary AxisBiotix Limited which is getting ready for their food supplement consumer study. The study, which will accept around 200 applicants, the participants will be asked to take a...

1 week, 6 days ago

3 min read